rsc.Medtronic, Novalab and Roche promote the use of new technologies in the treatment of diabetes
- By virtue of an agreement with the Spanish Society of Diabetes (SED) the companies Medtronic, Novalab, and Roche, with the support of the Spanish Federation of Health Technology (FENIN) Federation of which they are part, will promote theUse of new technologies in the treatment of diabetes, under an agreement signed with the Spanish Diabetes Society (SED).
For Carlos Sisternas, director of the Spanish Federation of Health Technology Companies of Catalonia, "the signing of this agreement is a very important step for the health technology industry because it will help to enhance the use of new technologies in the treatment of thediabetes".
It is estimated that in Spain the use of new technologies, such as insulin bombs, is below 3%, a very remote figure of 15% on average in the developed countries of Europe and only comparable to that registered in very socio -culturally remote countriesSpain.
The main objectives of this agreement are to disseminate the advances that are taking place in the field of technologies applied to diabetes;Promote independent research to evaluate the impact of new technological proposals and telematics in the care of diabetic people, and guarantee the training of health personnel in technologies applied to diabetes to contribute to improve the health and quality of life of theaffected.
To achieve these objectives, an action plan has also been defined that includes a biannual survey, directed by the new thirst's work group, on the use of new technologies for the treatment of diabetes in Spain.
In addition to this survey, as part of the agreement will also be developed, scholarships for help to research on the impact of the application of new technologies to diabetological care, channels to disseminate information referring to diabetes and new technologies and a documentof consensus together with a quick guide on the use of continuous interstitial glucose monitoring systems.
Likewise, training courses will be held in technologies applied to diabetes aimed at health professionals who attend children and adults with diabetes and a symposium on diabetes and new technologies that will be integrated into each Congress of SED, among other activities.